IDEXX Laboratories, Inc. $IDXX Shares Purchased by Boston Family Office LLC

Key Points

• Boston Family Office LLC increased its stake in IDEXX Laboratories by 4.7%, holding 28,658 shares worth approximately $12.04 million as of the latest SEC filing.
• IDEXX reported a strong earnings performance for the quarter, with $3.63 earnings per share that exceeded analysts' expectations by $0.35 and a 10.6% year-over-year revenue growth.
• Insider trading activity has been notable, with CEO Jonathan Jay Mazelsky and EVP Michael Lane selling significant shares, indicating a decrease in their positions of 25.99% and 54.11%, respectively.

Boston Family Office LLC lifted its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 4.7% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 28,658 shares of the company's stock after acquiring an additional 1,277 shares during the period. Boston Family Office LLC's holdings in IDEXX Laboratories were worth $12,035,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in IDXX. MorganRosel Wealth Management LLC bought a new stake in shares of IDEXX Laboratories in the 1st quarter valued at approximately $26,000. Migdal Insurance & Financial Holdings Ltd. increased its holdings in IDEXX Laboratories by 55.6% during the 1st quarter. Migdal Insurance & Financial Holdings Ltd. now owns 84 shares of the company's stock worth $35,000 after purchasing an additional 30 shares during the period. Colonial Trust Co SC boosted its position in IDEXX Laboratories by 84.8% during the 4th quarter. Colonial Trust Co SC now owns 85 shares of the company's stock valued at $35,000 after acquiring an additional 39 shares in the last quarter. Bank of Jackson Hole Trust boosted its position in IDEXX Laboratories by 328.6% during the 1st quarter. Bank of Jackson Hole Trust now owns 90 shares of the company's stock valued at $39,000 after acquiring an additional 69 shares in the last quarter. Finally, Itau Unibanco Holding S.A. boosted its position in shares of IDEXX Laboratories by 540.0% in the 4th quarter. Itau Unibanco Holding S.A. now owns 96 shares of the company's stock worth $40,000 after purchasing an additional 81 shares in the last quarter. 87.84% of the stock is owned by institutional investors.

Analysts Set New Price Targets

IDXX has been the subject of a number of research reports. Jefferies Financial Group assumed coverage on IDEXX Laboratories in a research report on Tuesday, July 1st. They set a "buy" rating and a $625.00 price target for the company. JPMorgan Chase & Co. boosted their price objective on IDEXX Laboratories from $550.00 to $675.00 and gave the stock an "overweight" rating in a research note on Monday, August 4th. BTIG Research upped their price objective on IDEXX Laboratories from $545.00 to $785.00 and gave the company a "buy" rating in a report on Tuesday, August 5th. Stifel Nicolaus set a $640.00 price target on IDEXX Laboratories in a research note on Monday, August 4th. Finally, Leerink Partners upped their price objective on IDEXX Laboratories from $580.00 to $600.00 and gave the stock an "outperform" rating in a research report on Thursday, July 17th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and three have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $649.44.

IDEXX Laboratories Price Performance

Shares of IDXX traded up $3.4130 during mid-day trading on Wednesday, reaching $640.1230. 235,145 shares of the company's stock were exchanged, compared to its average volume of 725,007. The company has a quick ratio of 0.79, a current ratio of 1.11 and a debt-to-equity ratio of 0.31. The company has a 50-day simple moving average of $563.04 and a two-hundred day simple moving average of $490.56. IDEXX Laboratories, Inc. has a 52-week low of $356.14 and a 52-week high of $688.12. The company has a market cap of $51.21 billion, a price-to-earnings ratio of 53.19, a PEG ratio of 4.13 and a beta of 1.49.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its quarterly earnings data on Monday, August 4th. The company reported $3.63 earnings per share for the quarter, topping analysts' consensus estimates of $3.28 by $0.35. The business had revenue of $1.11 billion during the quarter, compared to analysts' expectations of $1.06 billion. IDEXX Laboratories had a net margin of 24.41% and a return on equity of 64.42%. The company's revenue was up 10.6% on a year-over-year basis. During the same period last year, the company posted $2.44 EPS. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. On average, sell-side analysts predict that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

Insider Buying and Selling

In other IDEXX Laboratories news, EVP Nimrata Hunt sold 7,143 shares of IDEXX Laboratories stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $630.43, for a total value of $4,503,161.49. Following the transaction, the executive vice president owned 18,007 shares in the company, valued at $11,352,153.01. This trade represents a 28.40% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Michael G. Erickson sold 406 shares of the company's stock in a transaction on Tuesday, August 12th. The stock was sold at an average price of $649.96, for a total transaction of $263,883.76. Following the sale, the executive vice president directly owned 11,287 shares of the company's stock, valued at approximately $7,336,098.52. This trade represents a 3.47% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 51,870 shares of company stock worth $32,877,757 over the last 90 days. Company insiders own 0.98% of the company's stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.